| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2020: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2019: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2018: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Outline of Final Research Achievements |
Primary central nervous system lymphoma (PCNSL) is a rare type of highly malignant non-Hodgkin lymphoma, which arises in the central nervous system. In our current study, we aimed to develop a new immunotherapy platform by combining therapies with oncolytic virus and chimeric antigen receptor（CAR）T cell. We initially established nine patient-derived PCNSL cell lines (PDCs) and found that PCNSLs are highly susceptible to infection with NDV. Next, we constructed single-chain variable fragment (scFV) against NDV-HN antigen. The anti-NDV-HN scFv was fused with synNotch gene and introduced into Jurkat T cells for creating NDV sensing cells. Co-culture of the synNotch-Jurkat cells with NDV-infected PCNSL-PDCs resulted in the induction of CD19-specific CAR. On the other hand, there was no significant cell cytotoxicity of PCNSL-PDCs by the co-culture probably due to low expression of CAR on the cell surface.
|
